ReviewTranslational oncology2026
PARP inhibitors target cellular energy metabolism: Mechanisms of action and clinical implications.
Review in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poly-ADP-ribose polymerase (PARP) is a multifunctional ribozyme that is involved in a variety of biological functions, including DNA repair, modulation of chromatin structure, RNA transcription, cell division, metabolism, mitochondrial biology, oxidative stress biology, and cell death and differentiation. PARP inhibitors (PARPi) are a new class of targeted drugs widely used in the treatment of cancer with BRCA1/2 mutations and non-malignant diseases. Although PARPi has been known to affect the energy metabolism of cells, its exact effects and mechanisms on this process have not yet been fully understood. In this review article, we aim to provide a comprehensive overview of the current understanding of PARPi's effects on various physiological processes involving cellular energy metabolism, highlighting the importance of further exploring how the human body maintains the balance of energy metabolism during PARPi therapy. We also highlight the importance of future studies on the relationship between PARPi treatment and the depletion of NAD+ levels, the activation of PARP1, or the transition between different patterns of energy metabolism, to provide more insights into the safety and efficacy of PARPi in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.